{"brief_title": "Study of CP-461 in Patients With Advanced Renal Cell Cancer", "brief_summary": "The purpose of this study is to determine the efficacy of CP-461 given twice-daily orally in locally advanced or metastatic renal cell cancer and to evaluate the safety profile of CP-461 in this patient population.", "condition": "Renal Cell Carcinoma", "intervention_type": "Drug", "intervention_name": "CP-461", "criteria": "Inclusion Criteria: 1. Measurable metastatic or locally advanced disease. 2. Histologically confirmed renal cell cancer. 3. No radiotherapy within 4 weeks prior to entering the study. No more than 1 prior systemic therapy for advanced disease. Prior adjuvant systemic therapy is allowed. Patients must have fully recovered from the acute effects of prior therapy. 4. Expected remaining life span > or = three months. 5. ECOG performance status 0-2. 6. > or = 18 years of legal age. 7. Male patients, or non-pregnant and non-lactating female patients who are either using adequate birth control, surgically sterile or post-menopausal. 8. Negative serum pregnancy test, if fertile female. 9. Willingness and ability to sign an informed consent document. Exclusion Criteria: 1. Uncontrolled or symptomatic brain metastases. 2. Use of an investigational medication or device within one month of initiating study therapy. 3. Absolute granulocyte count < or = 1500/mm3; Platelet count < or = 100,000/mm3; total serum bilirubin above the upper limit of normal; serum creatinine > or = 2.2 mg/dL; AST/ALT > 2.5 ULN. 4. Any condition or any medication which may interfere with the conduct of the study. 5. Current active malignancy other than renal cell cancer.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00036036.xml"}